Top

Published in:

01-04-2021 | Colchicine | Observational Research

COVID-19 outcomes in patients with familial Mediterranean fever: a retrospective cohort study

Authors: Serdar Can Güven, Abdulsamet Erden, Özlem Karakaş, Berkan Armağan, Eren Usul, Ahmet Omma, Orhan Küçükşahin

Published in: Rheumatology International | Issue 4/2021

Abstract

Aim of this study is to investigate the course of coronavirus disease 2019 (COVID-19), in our cohort of familial Mediterranean fever (FMF) patients in means of mortality, admission to hospital and/or intensive care unit and length of hospital stay.A retrospective cohort was formed from patients who have previously been followed with a diagnosis of FMF. Patients of this cohort were retrospectively evaluated for a positive severe acute respiratory syndrome-coronavirus 2 (SARS-CoV 2) polymerized chain reaction (PCR) test result and information regarding hospitalisation, intensive care unit admission and mortality were collected from medical records.Out of a total 496 FMF patients, 34 were detected to have a positive SARS-CoV 2 PCR test. Eighty-five point three percent of these patients were under colchicine treatment and 17.6% were under interleukin (IL)—1 inhibitor treatment. Eight of the 34 patients (23.9%) were found to be hospitalized, one of them was admitted to the intensive care unit and died thereafter (2.9%). An increasing trend in the frequency of comorbid diseases (presence of at least one comorbidity 64.7% in all patients vs 75.0% in hospitalized patients) and IL-1 inhibitor usage (17.6% in all patients vs 50.0% in hospitalized patients) was observed in hospitalized patients.Rates of comorbid diseases and IL-1 inhibitor use for FMF were observed to be increased in FMF patients hospitalized for COVID-19.

Mehta P, McAuley DF, Brown M et al (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395:1033–1034. https://doi.org/10.1016/S0140-6736(20)30628-0CrossRefPubMedPubMedCentral

Tufan A, Avanoğlu Güler A, Matucci-Cerinic M (2020) COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci 50:620–632. https://doi.org/10.3906/sag-2004-168CrossRefPubMedPubMedCentral

Fajgenbaum DC, June CH (2020) Cytokine storm. N Engl J Med 383:2255–2273. https://doi.org/10.1056/NEJMra2026131CrossRefPubMedPubMedCentral

Stella A, Lamkanfi M, Portincasa P (2020) Familial mediterranean fever and COVID-19: friends or foes? Front Immunol 18(11):574593. https://doi.org/10.3389/fimmu.2020.574593CrossRef

Tufan A, Lachmann HJ (2020) Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review. Turk J Med Sci 50:1591–1610. https://doi.org/10.3906/sag-2008-11CrossRefPubMedPubMedCentral

Batu ED, Özen S (2020) Implications of COVID-19 in pediatric rheumatology. Rheumatol Int 40:1193–1213. https://doi.org/10.1007/s00296-020-04612-6CrossRefPubMedPubMedCentral

Sandhu T, Tieng A, Chilimuri S et al (2020) A case control study to evaluate the impact of colchicine on patients admitted to the hospital with moderate to severe COVID-19 infection. Can J Infect Dis Med Microbiol 2020:8865954. https://doi.org/10.1155/2020/8865954CrossRefPubMedPubMedCentral

Brunetti L, Diawara O, Tsai A et al (2020) Colchicine to weather the cytokine storm in hospitalized patients with COVID-19. J Clin Med 9:2961. https://doi.org/10.3390/jcm9092961CrossRefPubMedCentral

Scarsi M, Piantoni S, Colombo E et al (2020) Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. Ann Rheum Dis 79:1286–1289. https://doi.org/10.1136/annrheumdis-2020-217712CrossRefPubMed

10.

Deftereos SG, Giannopoulos G, Vrachatis DA et al (2020) Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial. JAMA Netw Open 3:e2013136. https://doi.org/10.1001/jamanetworkopen.2020.13136CrossRefPubMedPubMedCentral

11.

Iglesias-Julián E, López-Veloso M, de-la Torre-Ferrera N et al (2020) High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely Ill COVID-19 patients. J Autoimmun 115:102537. https://doi.org/10.1016/j.jaut.2020.102537CrossRefPubMedPubMedCentral

12.

Huet T, Beaussier H, Voisin O et al (2020) Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol 2:e393–e400. https://doi.org/10.1016/S2665-9913(20)30164-8CrossRefPubMedPubMedCentral

13.

Kooistra EJ, Waalders NJB, Grondman I et al (2020) Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study. Crit Care 24:688. https://doi.org/10.1186/s13054-020-03364-wCrossRefPubMedPubMedCentral

14.

Balkhair A, Al-Zakwani I, Al Busaidi M et al (2020) Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: results of a prospective, open-label, interventional study. Int J Infect Dis 103:288–296. https://doi.org/10.1016/j.ijid.2020.11.149CrossRefPubMedPubMedCentral

15.

Erden A, Ozdemir B, Karakas O et al (2020) Evaluation of 17 patients with COVID-19 pneumonia treated with anakinra according to HScore, SOFA, MuLBSTA, and Brescia-COVID respiratory severity scale (BCRSS) scoring systems. J Med Virol. https://doi.org/10.1002/jmv.26473CrossRefPubMed

16.

Haslak F, Yildiz M, Adrovic A et al (2020) Management of childhood-onset autoinflammatory diseases during the COVID-19 pandemic. Rheumatol Int 40:1423–1431. https://doi.org/10.1007/s00296-020-04645-xCrossRefPubMedPubMedCentral

17.

Bourguiba R, Delplanque M, Vinit C et al (2020) Clinical course of COVID-19 in a cohort of 342 familial Mediterranean fever patients with a long-term treatment by colchicine in a French endemic area. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-218707CrossRefPubMed

18.

Meyts I, Bucciol G, Quinti I et al (2020) Coronavirus disease 2019 in patients with inborn errors of immunity: an international study. J Allergy Clin Immunol. https://doi.org/10.1016/j.jaci.2020.09.010CrossRefPubMedPubMedCentral

19.

FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors (2020) Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-218310CrossRef

20.

Sohar E, Gafni J, Pras M, Heller H (1967) Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 43:227–253CrossRefPubMed

21.

Hyrich KL, Machado PM (2020) Rheumatic disease and COVID-19: epidemiology and outcomes. Nat Rev Rheumatol. https://doi.org/10.1038/s41584-020-00562-2CrossRefPubMedCentral

22.

Terré A, Deshayes S, Savey L et al (2020) Cause of death and risk factors for mortality in AA amyloidosis: a French retrospective study. Eur J Intern Med 82:130–132. https://doi.org/10.1016/j.ejim.2020.08.012CrossRefPubMed

Title: COVID-19 outcomes in patients with familial Mediterranean fever: a retrospective cohort study
Authors: Serdar Can Güven
Abdulsamet Erden
Özlem Karakaş
Berkan Armağan
Eren Usul
Ahmet Omma
Orhan Küçükşahin
Publication date: 01-04-2021
Publisher: Springer Berlin Heidelberg
Keywords: Colchicine
Anakinra
Severe Acute Respiratory Syndrome Coronavirus
COVID-19
Familial Mediterranean Fever
Published in: Rheumatology International / Issue 4/2021
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-021-04812-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

COVID-19 outcomes in patients with familial Mediterranean fever: a retrospective cohort study

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2021

The impact of COVID-19 on rheumatology patients in a large UK centre using an innovative data collection technique: prevalence and effect of social shielding

Improving the quality of life of patients with rheumatoid arthritis after rehabilitation irrespective of the level of disease activity

Occupational mimics of rheumatoid arthritis: hair dye-induced arthritis

Psoas abscess during treatment with intravenous tocilizumab in a patient with rheumatoid arthritis: a case-based review

Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry

Publication activity in the field of Sjögren’s syndrome: a ten-year Web of Science based analysis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page